{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:08:57Z","timestamp":1789186137633,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100011736","name":"Ministerium f\u00fcr Wirtschaft, Arbeit und Wohnungsbau Baden-W\u00fcrttemberg","doi-asserted-by":"publisher","award":["AZ 35-4223.10\/8"],"award-info":[{"award-number":["AZ 35-4223.10\/8"]}],"id":[{"id":"10.13039\/501100011736","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"DOI":"10.1007\/s11357-026-02495-2","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:31:52Z","timestamp":1789183912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring TIMP2 genetics and CSF levels in Parkinson\u2019s disease: biomarkers of neurodegeneration and ageing"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7066-7749","authenticated-orcid":false,"given":"Milan","family":"Zimmermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Fandrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Jakobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Wurster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Lerche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrzad","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Deuschle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Schneiderhan-Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Joos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Brockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Roeben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"2495_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1017\/S1041610207005790","volume":"20","author":"S Lorenzl","year":"2008","unstructured":"Lorenzl S, Buerger K, Hampel H, Beal MF. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. Int Psychogeriatr. 2008;20:67\u201376.","journal-title":"Int Psychogeriatr"},{"key":"2495_CR2","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nature22067","volume":"544","author":"JM Castellano","year":"2017","unstructured":"Castellano JM, Mosher KI, Abbey RJ, McBride AA, James ML, Berdnik D, et al. Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. Nature. 2017;544:488\u201392.","journal-title":"Nature"},{"key":"2495_CR3","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1038\/s41380-023-02296-5","volume":"28","author":"AC Ferreira","year":"2023","unstructured":"Ferreira AC, Hemmer BM, Philippi SM, Grau-Perales AB, Rosenstadt JL, Liu H, et al. Neuronal TIMP2 regulates hippocampus-dependent plasticity and extracellular matrix complexity. Mol Psychiatry. 2023;28:3943\u201354.","journal-title":"Mol Psychiatry"},{"key":"2495_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1006\/exnr.2002.8019","volume":"178","author":"S Lorenzl","year":"2002","unstructured":"Lorenzl S, Albers DS, Narr S, Chirichigno J, Beal MF. Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson\u2019s disease. Exp Neurol. 2002;178:13\u201320.","journal-title":"Exp Neurol"},{"key":"2495_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002672","volume":"95","author":"YC Chen","year":"2016","unstructured":"Chen YC, Wu YR, Mesri M, Chen CM. Associations of matrix metalloproteinase-9 and tissue inhibitory factor-1 polymorphisms with Parkinson disease in Taiwan. Medicine (Baltimore). 2016;95:e2672.","journal-title":"Medicine (Baltimore)"},{"key":"2495_CR6","doi-asserted-by":"crossref","unstructured":"Tuna G, Yener GG, Oktay G, Islekel GH, FG KI. Evaluation of matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in plasma from patients with neurodegenerative dementia. J Alzheimers Dis 2018;66,1265\u20131273.","DOI":"10.3233\/JAD-180752"},{"key":"2495_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00702-017-1821-9","volume":"125","author":"KA Jellinger","year":"2018","unstructured":"Jellinger KA. Dementia with Lewy bodies and Parkinson\u2019s disease-dementia: current concepts and controversies. J Neural Transm (Vienna). 2018;125:615\u201350.","journal-title":"J Neural Transm (Vienna)"},{"key":"2495_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/mds.27884","volume":"35","author":"S Lerche","year":"2020","unstructured":"Lerche S, Wurster I, Roeben B, Zimmermann M, Riebenbauer B, Deuschle C, et al. Parkinson\u2019s disease: glucocerebrosidase 1 mutation severity is associated with CSF alpha-synuclein profiles. Mov Disord. 2020;35:495\u20139.","journal-title":"Mov Disord"},{"key":"2495_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2495_CR10","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N, Movement Disorder Society UPDRS Revision Task Force","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N, Movement Disorder Society UPDRS Revision Task Force. Movement disorder society-sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129\u201370.","journal-title":"Mov Disord"},{"key":"2495_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88\u2013100.","journal-title":"Neurology"},{"key":"2495_CR12","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"2495_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"2495_CR14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/jgs.14779","volume":"65","author":"D Bergeron","year":"2017","unstructured":"Bergeron D, Flynn K, Verret L, Poulin S, Bouchard RW, Bocti C, et al. Multicenter validation of an MMSE-MoCA conversion table. J Am Geriatr Soc. 2017;65:1067\u201372.","journal-title":"J Am Geriatr Soc"},{"key":"2495_CR15","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1212\/WNL.0b013e3181c34b47","volume":"73","author":"S Hoops","year":"2009","unstructured":"Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73:1738\u201345.","journal-title":"Neurology"},{"key":"2495_CR16","volume-title":"Manual for the Beck Depression Inventory-II","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996."},{"key":"2495_CR17","doi-asserted-by":"publisher","first-page":"247 e249","DOI":"10.1016\/j.neurobiolaging.2017.05.009","volume":"57","author":"C Blauwendraat","year":"2017","unstructured":"Blauwendraat C, Faghri F, Pihlstrom L, Geiger JT, Elbaz A, Lesage S, et al. NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiol Aging. 2017;57:247 e249-247 e213.","journal-title":"Neurobiol Aging"},{"key":"2495_CR18","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","volume":"71","author":"S Palmqvist","year":"2014","unstructured":"Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71:1282\u20139.","journal-title":"JAMA Neurol"},{"key":"2495_CR19","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.neurobiolaging.2007.08.019","volume":"30","author":"L Glodzik-Sobanska","year":"2009","unstructured":"Glodzik-Sobanska L, Pirraglia E, Brys M, de Santi S, Mosconi L, Rich KE, et al. The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer\u2019s disease. Neurobiol Aging. 2009;30:672\u201381.","journal-title":"Neurobiol Aging"},{"key":"2495_CR20","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1002\/acn3.51676","volume":"9","author":"L Vermunt","year":"2022","unstructured":"Vermunt L, Otte M, Verberk IMW, Killestein J, Lemstra AW, van der Flier WM, et al. Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface. Ann Clin Transl Neurol. 2022;9:1832\u20137.","journal-title":"Ann Clin Transl Neurol"},{"key":"2495_CR21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00702-021-02351-x","volume":"128","author":"I Winkel","year":"2021","unstructured":"Winkel I, Ermann N, Zelwetro A, Sambor B, Mroczko B, Kornhuber J, et al. Cerebrospinal fluid alpha synuclein concentrations in patients with positive AD biomarkers and extrapyramidal symptoms. J Neural Transm (Vienna). 2021;128:817\u201325.","journal-title":"J Neural Transm (Vienna)"},{"key":"2495_CR22","doi-asserted-by":"publisher","first-page":"15078","DOI":"10.1074\/jbc.M114.610931","volume":"290","author":"M Hernandez-Guillamon","year":"2015","unstructured":"Hernandez-Guillamon M, Mawhirt S, Blais S, Montaner J, Neubert TA, Rostagno A, et al. Sequential amyloid-beta degradation by the matrix metalloproteases MMP-2 and MMP-9. J Biol Chem. 2015;290:15078\u201391.","journal-title":"J Biol Chem"},{"key":"2495_CR23","doi-asserted-by":"publisher","first-page":"24566","DOI":"10.1074\/jbc.M602440200","volume":"281","author":"P Yan","year":"2006","unstructured":"Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, et al. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem. 2006;281:24566\u201374.","journal-title":"J Biol Chem"},{"key":"2495_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12081196","author":"A Trentini","year":"2022","unstructured":"Trentini A, Manfrinato MC, Castellazzi M, Bellini T. Sex-related differences of matrix metalloproteinases (MMPs): new perspectives for these biomarkers in cardiovascular and neurological diseases. J Pers Med. 2022. https:\/\/doi.org\/10.3390\/jpm12081196.","journal-title":"J Pers Med"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-026-02495-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-026-02495-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-026-02495-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:31:55Z","timestamp":1789183915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-026-02495-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":24,"alternative-id":["2495"],"URL":"https:\/\/doi.org\/10.1007\/s11357-026-02495-2","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"8 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants gave written informed consent. The study was approved by the Ethics Committee of the Faculty of Medicine at the University of T\u00fcbingen (Project-Nr. 458\/2023BO2). All procedures were in accordance with the Declaration of Helsinki (1975).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Kathrin Brockmann received Research Grants from the Michael J Fox Foundation for Parkinson\u2019s Research (\u201cLRRK2 Kinase Activity,\u201d \u201cInfluence of Inflammatory Profiles on PD Phenotype and Progression,\u201d \u201cPrevent Dementia in GBA1-associated PD\u201d), from the University of T\u00fcbingen (\u201cEndophenotyping of GBA1-PD\u201d), from the German Society for Parkinson DPG, from the State Ministry of Baden-W\u00fcrttemberg for Economic Affairs, Labour and Tourism (\u201cPredictive Diagnostic of immune-associated diseases for personalized medicine,\u201d AZ 35-4223.10\/8), from the Else Kr\u00f6ner Fresenius Stiftung (\u201cClinBrain\u201d), and from the German Research Foundation DFG (\u201cCORO-TREND\u201d). She serves on advisory boards for F. Hoffmann-La Roche Ltd and VanqaBio. She received speaker honoraria from Abbvie, Lundbeck, UCB and Zambon.Christian Deuschle has nothing to disclose.Prof. Dr. Thomas Gasser serves on the editorial board of the Journal of Parkinson\u2019s Disease. He holds a patent re: KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative diseases. Prof. Gasser has received speaker\u2019s honoraria from UCB Pharma, Novartis, Sanofi and MedUpdate. He has received consulting fees from Bayer AG, BlueRock Therapeutics and Biogen. He is Chairman of the Scientific Advisory Board of the \u201cJoint Programming for Neurodegenerative Diseases\u201d program, funded by the European Commission. He has received grant support from the German Research Foundation (DFG), the German Federal Ministry of Education and Research (BMBF), the Ministry for Science, Research and Art Baden-W\u00fcrttemberg (MWK), the European Commission, the Helmholtz Association and The Michael J. Fox Foundation.Madeleine Fandrich has nothing to disclose.Dr. Meike Jakobi has nothing to disclose.Dr. Thomas O. Joos has nothing to disclose.Dr. Stefanie Lerche has nothing to disclose.Dr. Benjamin R\u00f6ben has received a research grant from the University of T\u00fcbingen (Clinician Scientist; Project-Nr. 480-0-0).Dr. Nicole Schneiderhan-Marra has received funding from the State Ministry of Baden-W\u00fcrttemberg for Economic Affairs, Labour and Tourism (\u201cPredictive Diagnostic of immune-associated diseases for personalized medicine,\u201d AZ 35-4223.10\/8).Claudia Schulte has nothing to disclose.Dr. Isabel Wurster receives funding from The Michael J. Fox Foundation (MJFF) as an Edmond J. Safra Fellow in Movement Disorders.Dr. Milan Zimmermann has received a research grant from the University of T\u00fcbingen (Clinician Scientist; Project-Nr. 481-0-0).Shahrzad Zimmermann has nothing to disclose.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}